Telix Pharmaceuticals enters into Exclusive Licence Agreement with Osaka University
Telix announces an exclusive Intellectual Property (IP) licence with Osaka University for a novel radiochemistry technology.
Telix Quarterly Shareholder Update – CEO Presentation and Transcript of Investor Conference Call
Telix Pharmaceuticals is pleased to provide its Quarterly Shareholder Update presentation and the transcript of CEO Dr Chris Behrenbruch’s conference call with investors.
Activity Report and Sales Note to Accompany Appendix 4C
Telix provides its Appendix 4C for the quarter ending 31st March 2020 and a Q1 2020 sales update for its prostate cancer imaging product
AGM Notice of Meeting – Telix Pharmaceuticals Limited
Telix Pharmaceuticals provides notice of The Annual General Meeting of the Shareholders on Tuesday 12 May 2020
Telix Pharmaceuticals Enters Commercial Distribution Agreement for Prostate Cancer Diagnostic
Telix Pharmaceuticals (U.S.) Inc. is pleased to announce it has entered into a commercial agreement with Cardinal Health
Telix Completes Acquisition of European Radiopharmaceutical Production Facility
Telix is pleased to announce it has now completed the acquisition of a licensed radiopharmaceutical production facility in Seneffe, Belgium
Telix Pharmaceuticals and partners receive $500K research grant from Government funded Innovative Manufacturing CRC
Telix and partners receive $500K research grant from Government-funded Innovative Manufacturing CRC to advance manufacturing of novel cancer drugs
Business Update : COVID-19
Telix provides an update on the Company’s risk management assessment of the novel coronavirus (COVID-19) pandemic.
Leader in Prostate Cancer Imaging Prof. Frederik L. Giesel Joins Scientific Advisory Board
Telix Pharmaceuticals Limited is pleased to announce that Professor Dr. Frederik L. Giesel, MD, MBA has joined Telix’s Scientific Advisory Board (SAB).
Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)
Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its submission of an NDA for TLX591-CDx